On Thursday, biopharmaceutical Company
XORTX Therapeutics Inc. (CSE: XRX, OTCQB: XRTXF, Forum) announced that Dr. Anjay Rastogi MD PhD had joined its clinical advisory board.
Dr. Rastogi a Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, where he is also the director of the CORE PKD (Polycystic Kidney Disease) Center. He has clinical experience treating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
To find out more about him and his work, click
here.
XORTX
was recently covered by Stockhouse Editorial, looking at its development of therapies to treat progressive kidney disease, kidney injury due to coronavirus infection and progressive kidney disease due to diabetes.
FULL DISCLOSURE: XORTX Therapeutics Inc. is a paid client of Stockhouse Publishing.